PARIS and CAMBRIDGE, Mass. — November 11, 2025 — Leads & Copy — Nanobiotix (Euronext: NANO – NASDAQ: NBTX), a late-clinical stage biotechnology firm focused on nanotherapeutic approaches for cancer and other major diseases, announced today its management will participate in a fireside chat at the Jefferies London Healthcare Conference on Monday, November 17, 2025.
The fireside chat will take place in London, UK, at 3pm GMT / 10am ET / 4pm CET. Nanobiotix Chief Executive Officer Laurent Levy and Chief Financial & Business Officer Bart van Rhijn will be the presenters.
A live webcast of the fireside chat will be available on the events page of the Investors section of Nanobiotix’s website. A replay will be available after the event.
Nanobiotix, incorporated in 2003, is based in Paris, France, with subsidiaries in Cambridge, Massachusetts, and other locations. It has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.
The company owns more than 25 patent families associated with three nanotechnology platforms with applications in oncology, bioavailability and biodistribution, and disorders of the central nervous system.
Brandon Owens, VP, Communications, +1 (617) 852-4835, contact@nanobiotix.com
Joanne Choi, VP, Investor Relations (US), +1 (713) 609-3150, Ricky Bhajun, Director, Investor Relations (EU), +33 (0) 79 97 29 99, investors@nanobiotix.com
Caroline Hardy, HARDY, +33 06 70 33 49 50, carolinehardy@outlook.fr
Becky Lauer, uncapped, +1 (646) 286-0057, uncappednanobiotix@uncappedcommunications.com
Source: Nanobiotix
